Overview

Apatinib Plus Docetaxel in Advanced Non-squamous Non-small Cell Lung Cancer(NSCLC)

Status:
Unknown status
Trial end date:
2020-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study was to evaluate the effectiveness and safety of apatinib combined with docetaxel in NSCLC.
Phase:
Phase 2
Details
Lead Sponsor:
Affiliated Hospital of North Sichuan Medical College
Collaborator:
Jiangsu HengRui Medicine Co., Ltd.
Treatments:
Apatinib
Docetaxel